Clinical trials: Renal Dysfunction
Chronic Renal Insufficiency, Type 2 Diabetes Mellitus
A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)
This is a 2-part study in participants with renal impairment and matched healthy participants to investigate the effect of impaired renal function on the plasma and urine levels of omarigliptin (MK-3102) after taking a single 3…
- Trial name
- NCT01407276
- Testing
- Omarigliptin
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease, Huntington's Disease
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
This study is to compare the pharmacokinetics of Dimebon in subjects with severe renal impairment to subjects with normal renal function after oral administration of a single oral 20-mg dose of Dimebon.
- Trial name
- NCT00824590
- Testing
- Dimebon
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Renal Failure
Initiative for Patient Outcomes in Dialysis - Peritoneal Dialysis (PD) (IPOD-PD Study)
The aim of the study is to asses the hydration status of incident peritoneal dialysis (PD) patients and its evolution over a period of four years, independent of the PD treatment modality (APD or CAPD) and the PD solution type.
- Trial name
- IPOD-PD (NCT01285726)
- Testing
- Non-interventional study
- Where
- 134 sites in Austria, Belgium and 26 more
- Volunteers
- 1,092 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Renal Insufficiency, Healthy
A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body
The primary objective of the current study is to investigate the influence of moderate renal impairment on the pharmacokinetics of multiple doses in comparison to a matched control group with normal renal function.
- Trial name
- NCT03302091
- Testing
- BI 1467335
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease(CKD), Progression, Disease
Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease
The goal of this longitudinal observational study is to estimate the performances of a candidate proteomic biomarker to identify patients at short term risk of chronic kidney disease (CKD) progression, in CKD patients attending…
- Trial name
- KidneySign (NCT06962891)
- Testing
- CKD progression biomarker
- Where
- 3 sites in Austria, France and 1 more
- Volunteers
- 213 people
- Sponsor
- Angel Argiles
Chronic Kidney Disease, Hyperphosphatemia
A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis
The purpose of this study is to summarize the percentage of participants achieving age-specific Kidney Disease Outcomes Quality Initiative (KDOQI) targets for serum phosphorus in hyperphosphatemic children and adolescents with…
- Trial name
- NCT01696279
- Testing
- Lanthanum Carbonate, Calcium Carbonate
- Where
- 22 sites in Argentina, Chile and 7 more
- Volunteers
- 63 people
- Sponsor
- Shire
Renal Impairment
Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants
The purpose of this study is to assess the PK, tolerability, and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment compared to matched control participants with normal renal function.
- Trial name
- NCT06708520
- Testing
- Rupatadine
- Where
- 7 sites in Portugal, Spain
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Noucor Health S.A.
Type 2 Diabetes Mellitus
Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function
To compare and analysis pharmacokinetics of PEX 168 in patients with renal insufficiency or normal renal function who were administrated subcutaneously single dose PEX168.To evaluate dose adjustment of PEX168 administered in…
- Trial name
- NCT02467790
- Testing
- PEX168
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Kidney Disease, Hyperphosphatemia Undergoing Hemodialysis
Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan
The objective of this study is to assess PK, safety and tolerability of a single oral dose of ASP3325 and to assess PD, PK and safety of repeated oral doses of ASP3325 administered t.i.d. before or just after each meal
- Trial name
- NCT02510274
- Testing
- ASP3325
- Where
- 5 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc
Dyslipidemia
Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers
To analyze efficacy of fluvastatin on patients with chronic renal disease by analyzing certain inflammatory markers. In addition, tolerability and safety will also be evaluated in a Spanish population.
- Trial name
- NCT00171262
- Testing
- Fluvastatin
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Novartis
Diabetic Kidney Disease (DKD)
Rubix LS Diabetic Kidney Disease (DKD) Registry Study
Diabetic kidney disease (DKD) is a common complication of type 2 diabetes that can lead to kidney failure and increases the risk of cardiovascular disease.
- Trial name
- NCT07348718
- Testing
- Kidney-Protective Therapies Used in Routine Care
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Rubix LS
Chronic Kidney Failure
Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line
The primary objective is to collect data to evaluate the biocompatibility of two types of blood circuit, already on the market.
- Trial name
- NCT00804453
- Testing
- Cartridge blood set, Standard blood line
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Vantive Health LLC
End-Stage Renal Disease, End-Stage Kidney Disease
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an…
- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Trial name
- NCT05027074
- Testing
- MK-2060
- Where
- 120 sites in United States, Argentina and 13 more
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Arterial Hypertension, Chronic Kidney Disease
PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of Russia
This study is a multi-centre, non-interventional, observational, prospective study with retrospective analysis. The main purpose of the study is to describe the rate of CKD diagnosis in patients with AH and CKD markers.
- Trial name
- PRIORITY-CKD (NCT06372431)
- Where
- 30 sites in Russia
- Volunteers
- 9,914 people
- Sponsor
- AstraZeneca
End Stage Renal Disease, End Stage Renal Failure on Dialysis
First-in-Human (FIH) Study of the Xeltis Hemodialysis Access Graft
A feasibility study is to assess the preliminary safety and performance of the Xeltis hemodialysis access (aXess) graft.
- Trial name
- aXess-FIH (NCT04898153)
- Testing
- aXess
- Where
- 6 sites in Belgium, Italy and 2 more
- Volunteers
- 20 people
- Sponsor
- Xeltis
Chronic Kidney Disease and Systemic Inflammation
A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation
This study is conducted to see how the ziltivekimab works in the body of Chinese people with chronic kidney disease and systemic inflammation.
- Trial name
- NCT05379829
- Testing
- Ziltivekimab
- Where
- 7 sites in China
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Kidney Failure, Chronic
Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands
This observational study will evaluate the clinical benefit of Zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands.
- Trial name
- NCT01273597
- Where
- 11 sites in Hungary
- Volunteers
- 60 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Kidney Diseases, Kidney Injury
A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants
Part I (bioequivalence) will evaluate the bioequivalence of the Oversea Manufactured Sample (used in the MediBeacon Phase 3 Study 100-103; NCT05425719) and Domestic Manufactured Sample in Single Intravenous Dose of MB-102…
- Conditions
- Kidney Diseases, Kidney Injury, Kidney Failure
- Trial name
- NCT05943977
- Testing
- MB-102 DMID, MB-102 OMID, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- Where
- 2 sites in China
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Anemia
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
The purpose of this study is to evaluate whether hemodialysis patients on peginesatide can be converted to epoetin alfa by using a predefined conversion table while achieving a stable hemoglobin.
- Trial name
- NCT01737879
- Testing
- Peginesatide, Epoetin alfa
- Where
- 23 sites in United States
- Volunteers
- 41 people
- Sponsor
- Amgen
Healthy Volunteers, Chronic Kidney Disease
A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease
The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease.
- Trial name
- NCT07231679
- Testing
- IGT-303
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Ingenia Therapeutics INC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.